ProMIS Neurosciences Inc (PMN.CA) Stock News

ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights

Mentions: PMN

ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology

Mentions: PMN

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused...

Mentions: PMN

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024

Mentions: PMN

ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference

Preclinical data showed strong antibody responses with no measurable pro-inflammatory T cell responses against AßO and support novel approach for potential...

Mentions: PMN

ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference

Mentions: PMN

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose dependent...

Mentions: PMN

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

Mentions: PMN

ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing

$30.3 million financing upfront with up to an additional $92.4 million tied to exercise of warrants, with certain of the warrants subject to shareholder...

Mentions: PMN

ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing

Mentions: PMN

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024...

Mentions: PMN

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024

Mentions: PMN

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

Study results support differentiation of PMN310 from other amyloid-beta-directed antibodies...

Mentions: PMN

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

Study results support differentiation of PMN310 from other amyloid-beta-directed antibodies

Mentions: PMN

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

Study results support ProMIS’ TDP-43 misfolding-specific epitope as a potential therapeutic target for Amyotrophic Lateral Sclerosis (ALS)

Mentions: PMN

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April

CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 04, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company...

Mentions: PMN

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April

Mentions: PMN

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024...

Mentions: PMN

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024

Mentions: PMN

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

Adds Key U.S. and International Patent Allowances to Further Protect the Company’s Monoclonal Antibody Therapeutic for the Treatment of Alzheimer’s...

Mentions: PMN

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

Adds Key U.S. and International Patent Allowances to Further Protect the Company’s Monoclonal Antibody Therapeutic for the Treatment of Alzheimer’s Disease

Mentions: PMN

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused...

Mentions: PMN

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

Mentions: PMN

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

Lead vaccine candidate selected for advancement against synucleinopathies including Multiple System Atrophy, Parkinson’s disease and Dementia with Lewy...

Mentions: PMN

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

Lead vaccine candidate selected for advancement against synucleinopathies including Multiple System Atrophy, Parkinson’s disease and Dementia with Lewy bodies

Mentions: PMN

ProMIS Neurosciences Issues Letter to Shareholders

Mentions: PMN

ProMIS Neurosciences, Inc. Announces Leadership Transition

Appoints Neil Warma, Industry Leader and ProMIS Board Member, as Interim Chief Executive Officer...

Mentions: PMN

ProMIS Neurosciences, Inc. Announces Leadership Transition

Appoints Neil Warma, Industry Leader and ProMIS Board Member, as Interim Chief Executive Officer

Mentions: PMN

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Study results published in Acta Neuropathologica Communications support targeting of RACK1 as a potential therapeutic approach for Amyotrophic Lateral...

Mentions: PMN

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Mentions: PMN

ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease

Advances novel monoclonal antibody designed to be highly selective for toxic oligomers of amyloid-beta (Aβ) in first-in-human study

Mentions: PMN

ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

Mentions: PMN

ProMIS Nerusciences to sell 22.4M shares for holders (TSX:PMN:CA)

ProMIS Nerusciences files prospectus for resale of common shares by selling stockholders. This is not an offer to sell securities. Filing update.

ProMIS Neurosciences Closes $20.4 Million Private Placement Financing

At-the-Market fundraise to support Company through several potentially value-creating milestones and beyond...

Mentions: PMN

ProMIS Neurosciences Closes $20.4 Million Private Placement Financing

At-the-Market fundraise to support Company through several potentially value-creating milestones and beyond

Mentions: PMN

ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Mentions: PMN

ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

TORONTO, Ontario and CAMBRIDGE, Massachusetts, Sept. 06, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company...

Mentions: PMN

ProMIS Neurosciences Announces $20.4 Million Private Placement Financing

Mentions: PMN

ProMIS Neurosciences Announces $20.4 Million Private Placement Financing

At-the-Market Fundraise supports Company through several potentially value-creating milestones and beyond TORONTO, Ontario and CAMBRIDGE, Massachusetts,...

Mentions: PMN

ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights

Mentions: PMN